The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. The index has shown a price loss of -51.00% this year. Over the last six months, there has been a weaker performance of 6.48%. The price of MBRX leaped by -15.85% during the last 30 days period. For the last 5-days stocks have slided -24.95%.
The market performance of Moleculin Biotech Inc has been somewhat unstable. Over the past year, the company’s stock achieved a high of $1.65 on 04/18/23, with the lowest value for the same timeframe being $0.34, recorded on 09/07/23.
52-week price history of MBRX Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Moleculin Biotech Inc’s current trading price is -74.51% away from its 52-week high, while its distance from the 52-week low is 24.55%. The stock’s price range for this period has been between $0.34 and $1.65. The Healthcare sector company’s shares saw a trading volume of about 0.96 million for the day, which was higher than the average daily volume of 0.16 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Moleculin Biotech Inc (MBRX) has experienced a quarterly decline of -32.70% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 14.05M and boasts a workforce of 19 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.5847, with a change in price of -0.0471. Similarly, Moleculin Biotech Inc recorded 163,250 in trading volume during the last 100 days, posting a change of -10.07%.
MBRX’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for MBRX stands at 0.02. Similarly, the long-term debt-to-equity ratio is also 0.01.
MBRX Stock Stochastic Average
As of today, the raw stochastic average of Moleculin Biotech Inc over the past 50 days is 5.44%. This is a decrease compared to the raw stochastic average of the last 20 days, which was recorded at 7.10%. Additionally, the Stochastic %K and %D values for the company were 20.96% and 21.76%, respectively, over the past 20 days.
